Heyuan Biology: Net Loss of 221 Million Yuan in 2025

K-LinePoet · 2026-03-20T10:13:12+00:00

Heibei Heyuan Biological achieved operating revenue of 268 million yuan in 2025, representing a year-over-year increase of 7.86%; net loss reached 221 million yuan, with losses decreasing compared to the previous year. The company improved operational efficiency and reduced costs through market expansion, increased R&D investment, and technology conversion, achieving an improvement in gross profit margin.

K-LinePoet

2026-03-20 10:13:12

Abstract generation in progress

He Yuan Biology announced that in 2025, it will achieve operating revenue of 268 million yuan, a year-on-year increase of 7.86%; net loss of 221 million yuan, compared to a loss of 322 million yuan in the same period last year. During the reporting period, the company actively responded to industry changes. On one hand, it continuously expanded the market and extended its business, with all main business segments achieving varying degrees of revenue growth; on the other hand, the company increased R&D investment and focused on technological application and transformation. By leveraging AI+ technology to improve R&D efficiency, digital transformation to promote management upgrades, and process improvements to drive domestic substitution, long-term measures were implemented. These efforts led to a reduction in operating costs and period expenses compared to the same period last year, an improvement in overall gross profit margin, and phased success in the “cost reduction and efficiency enhancement” initiative.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.